CAR-T therapies not cost-effective for diffuse large B-cell lymphoma

by

For patients with diffuse large B-cell lymphoma (DLBCL), the chimeric antigen receptor T-cell therapies (CAR-T) axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are not cost-effective, according to a study published online Dec. 5 in the Annals of Internal Medicine.

Leave A Comment

Your email address will not be published. Required fields are marked *